Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

15.38
-0.2900-1.85%
Post-market: 15.380.00000.00%19:35 EDT
Volume:1.21M
Turnover:18.74M
Market Cap:1.23B
PE:-33.08
High:16.07
Open:15.75
Low:15.33
Close:15.67
52wk High:25.77
52wk Low:3.50
Shares:80.02M
Float Shares:57.22M
Volume Ratio:0.58
T/O Rate:2.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4650
EPS(LYR):-0.4650
ROE:-16.94%
ROA:-7.64%
PB:5.28
PE(LYR):-33.08

Loading ...

Monte Rosa Therapeutics Inc - to Conduct and Sponsor Trial; Johnson & Johnson to Supply Erleada

THOMSON REUTERS
·
Mar 16

Monte Rosa Therapeutics Inc - to Initiate Phase 2 Study of Mrt-2359 With Apalutamide in Q3 2026

THOMSON REUTERS
·
Mar 16

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 11

Monte Rosa Therapeutics CEO Markus Warmuth Disposes of Common Shares

Reuters
·
Mar 05

Monte Rosa Therapeutics Principal Accounting Officer Edmund Dunn Disposes of Common Shares

Reuters
·
Mar 03

Monte Rosa Therapeutics Publishes Corporate Presentation on Molecular Glue Degraders and Targeted Protein Degradation Pipeline

Reuters
·
Feb 26

Monte Rosa Therapeutics (GLUE) Receives a Buy from Wedbush

TIPRANKS
·
Feb 25

TD Cowen Sticks to Their Buy Rating for Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Feb 25

Monte Rosa Therapeutics Chief Medical Officer Filip Janku Disposes of Common Shares

Reuters
·
Feb 25

Monte Rosa announces clinical data from Phase 1/2 study of MRT-2359

TIPRANKS
·
Feb 24

Monte Rosa to Launch Phase 2 Trial of MRT-2359 Plus AR Inhibitor in AR-Mutant mCRPC in Q3 2026

Reuters
·
Feb 24

Monte Rosa Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Reuters
·
Feb 23

Monte Rosa Therapeutics Inc Files for Mixed Shelf Offering, Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Feb 12

Monte Rosa Therapeutics Appoints Matthew Bowen as Corporate Controller

Reuters
·
Feb 11

13D Filings -- Barrons.com

Dow Jones
·
Jan 17

Monte Rosa Therapeutics Price Target Raised to $37.00/Share From $27.50 by Piper Sandler

Dow Jones
·
Jan 14

Monte Rosa Therapeutics CEO Markus Warmuth Reports Sale of Common Shares

Reuters
·
Jan 10

BUZZ-U.S. STOCKS ON THE MOVE-Broadcom, home lenders, First Solar

Reuters
·
Jan 09

Monte Rosa Therapeutics 11.125M share Secondary priced at $24.00

TIPRANKS
·
Jan 09

Press Release: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

Dow Jones
·
Jan 09